SUCCESSFUL CO-TREATMENT OF BCR-ABL LEUKEMIC CELLS WITH PONATINIB, AN ABL KINASE INHIBITOR, AND VORINOSTAT, A HISTONE DEACETYLASE INHIBITOR: A POTENTIAL TREATMENT FOR BCR-ABL POSITIVE LEUKEMIA CELLS

被引：0

作者：

Okabe, S. ^{[1
]}

Tauchi, T. ^{[1
]}

Kimura, S. ^{[2
]}

Maekawa, T. ^{[3
]}

Ohyashiki, K. ^{[1
]}

机构：

[1] Tokyo Med Univ, Tokyo, Japan

[2] Saga Univ, Saga, Japan

[3] Kyoto Univ Hosp, Kyoto, Japan

来源：

HAEMATOLOGICA | 2012年 / 97卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0521

引用

页码：210 / 210

页数：1

共 50 条

[31] The immunogenicity of Bcr-Abl-expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl-regulated antigens
Scheich, Florian
Duyster, Justus
Peschel, Christian
Bernhard, Helga
BLOOD, 2007, 110 (07) : 2556 - 2560
[32] Combination of the histone deacetylase inhibitor vorinostat and dasatinib increases apoptosis in Bcr-abl plus cells and reverses changes associated with CML progression.
Kretzner, Leo
Scuto, Anna
Juhasz, Agnes
Jove, Richard
Yen, Yun
Forman, Stephen J.
Kirschbaum, Mark
BLOOD, 2006, 108 (11) : 614A - 614A
[33] Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells
Nimmanapalli, R
Bali, P
O'Bryan, E
Fuino, L
Guo, F
Wu, J
Houghton, P
Bhalla, K
CANCER RESEARCH, 2003, 63 (22) : 7950 - 7958
[34] Inhibition of T315I Bcr-Abl and other imatinib-resistant Bcr-Abl mutants by the selective Abl kinase inhibitor SGX70393.
O'Hare, Thomas
Eide, Christopher A.
Tyner, Jeffrey W.
Wong, Matthew J.
Smith, Caitlyn A.
Corbin, Amie S.
Buchanan, Sean
Jessen, Katayoun A.
Tang, Crystal
Holme, Kevin
Burley, Stephen K.
Deminger, Michael W. N.
BLOOD, 2006, 108 (11) : 400A - 401A
[35] Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
H Pfeifer
T Lange
S Wystub
B Wassmann
J Maier
A Binckebanck
A Giagounidis
M Stelljes
M Schmalzing
U Dührsen
L Wunderle
H Serve
P Brück
A Schmidt
D Hoelzer
O G Ottmann
Leukemia, 2012, 26 : 1475 - 1481
[36] Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
Pfeifer, H.
Lange, T.
Wystub, S.
Wassmann, B.
Maier, J.
Binckebanck, A.
Giagounidis, A.
Stelljes, M.
Schmalzing, M.
Duehrsen, U.
Wunderle, L.
Serve, H.
Brueck, P.
Schmidt, A.
Hoelzer, D.
Ottmann, O. G.
LEUKEMIA, 2012, 26 (07) : 1475 - 1481
[37] Serial Analysis of BCR-ABL Kinase Domain Mutations Prior to and During Imatinib Treatment for Newly Diagnosed and Recurrent BCR-ABL Positive Acute Lymphoblastic Leukemia.
Pfeifer, Heike
Wystub, Sylvia
Wassmann, Barbara
Maier, Jaqueline
Lange, Thoralf
Hochhaus, Andreas
Hoelzer, Dieter
Ottmann, Oliver
BLOOD, 2009, 114 (22) : 806 - 806
[38] Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
Seiichi Okabe
Tetsuzo Tauchi
Yuko Tanaka
Shinya Kimura
Taira Maekawa
Kazuma Ohyashiki
Cancer Cell International, 13
[39] Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
Takeuchi, Asako
Kondo, Toshinori
Tasaka, Taizo
Yamada, Seiko
Hirose, Tadashi
Fukuda, Hirofumi
Shimizu, Risa
Matsuhashi, Yoshiko
Kondo, Eisei
Wada, Hideho
LEUKEMIA RESEARCH REPORTS, 2021, 15
[40] Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
Okabe, Seiichi
Tauchi, Tetsuzo
Tanaka, Yuko
Kimura, Shinya
Maekawa, Taira
Ohyashiki, Kazuma
CANCER CELL INTERNATIONAL, 2013, 13

← 1 2 3 4 5 →